Skip to main content
CF PharmTech, Inc. logo

CF PharmTech, Inc. — Investor Relations & Filings

Ticker · 2652 HKEX Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2025-11-26 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2652

About CF PharmTech, Inc.

https://www.cfpharmtech.com

CF PharmTech, Inc. is a commercial-stage specialty pharmaceutical company specializing in the research, development, manufacturing, and commercialization of complex drug delivery systems, primarily focusing on inhalation technologies. The company develops treatments for major respiratory conditions, including asthma, Chronic Obstructive Pulmonary Disease (COPD), and allergic rhinitis. Its core product platforms encompass Inhalation Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), inhalation liquid preparations (nebulizers), and nasal sprays. The firm also leverages advanced formulation techniques, such as liposomes, to enhance drug efficacy and delivery.

Recent filings

Filing Released Lang Actions
Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 1% confidence The document is a notification sent to non-registered shareholders regarding the company's adoption of electronic dissemination of corporate communications, in compliance with the Hong Kong Stock Exchange Listing Rules. It provides instructions on how shareholders can access documents electronically or request printed copies via an attached Reply Form. This is a standard administrative communication regarding the distribution of corporate materials, not a financial report or a specific regulatory filing of results, and thus falls under the category of a Regulatory Filing (RNS) or a general administrative notice.
2025-11-26 English
Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 1% confidence The document is a formal notice from CF PharmTech, Inc. to its shareholders regarding the arrangement for electronic dissemination of corporate communications, in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. It includes a reply form for shareholders to provide their contact details or request printed copies. This is a standard administrative communication regarding corporate reporting procedures, not a financial report itself, and fits the definition of a Regulatory Filing (RNS) or a general corporate announcement.
2025-11-26 English
INSIDE INFORMATION PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY
Share Issue/Capital Change Classification · 1% confidence The document is an announcement regarding the 'Proposed Implementation of H Share Full Circulation' by CF PharmTech, Inc. It details the conversion of domestic unlisted shares into H shares, which is a change in the company's capital structure and share classification. This falls under the category of share capital changes or capital structure updates. Given the specific nature of 'H Share Full Circulation' announcements in the Hong Kong market, it aligns best with the 'Share Issue/Capital Change' (SHA) category as it involves the conversion and listing of shares.
2025-11-25 English
VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE MANDATE
Transaction in Own Shares Classification · 1% confidence The document is a voluntary announcement from CF PharmTech, Inc. regarding a 'Proposed Share Repurchase Mandate'. It outlines the Board's approval of a resolution to seek shareholder authorization at an upcoming EGM to repurchase H shares. Since this is an announcement of a proposed mandate rather than the actual execution of a share buyback (which would be POS) or a formal proxy statement (which would be PSI), it falls under the category of general regulatory announcements regarding corporate actions.
2025-11-13 English
PROPOSED ADOPTION OF H SHARE AWARD SCHEME PROPOSED AUTHORIZATION TO THE BOARD AND/OR AUTHORIZED PERSON TO HANDLE MATTERS RELATING TO THE H SHARE AWARD SCHEME
Share Issue/Capital Change Classification · 1% confidence The document is an announcement from CF PharmTech, Inc. regarding the 'Proposed Adoption of H Share Award Scheme' and the 'Proposed Authorization to the Board' to handle matters related to this scheme. It outlines the purpose of the scheme, its compliance with the Listing Rules, and the requirement for shareholder approval at a general meeting. Since this is a regulatory announcement regarding a corporate action (share award scheme) that does not fit into specific categories like dividends, director dealings, or financial reports, and it is not a full proxy statement itself but an announcement of the proposal, it falls under the general regulatory filing category.
2025-11-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a mandatory monthly return filed under the Hong Kong Stock Exchange Listing Rules (Chapter 19B) detailing movements (or confirmations of no movement) in authorized, registered, issued, and treasury share capital for the month ended 31 October 2025. It is not an earnings release, financial report, or proxy statement, nor is it an announcement of a specific capital financing event or stock split. It is a routine regulatory filing required by the exchange. Therefore it falls under the general “Regulatory Filings” category (RNS).
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.